Michel Tod
Overview
Explore the profile of Michel Tod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
1368
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cnudde A, Allely C, Biset N, Champy P, Fouilhe N, Huret F, et al.
BMC Complement Med Ther
. 2024 Dec;
24(1):414.
PMID: 39695590
Background: While more and more people tend to use herbal products thinking they are safer than conventional western medicine, the reality is other. If natural products are bio-active and possess...
2.
Moreau F, Decaudin B, Tod M, Odou P, Simon N
Eur J Hosp Pharm
. 2024 Aug;
PMID: 39137973
Objectives: Several drug-drug interaction (DDI) checkers such as DDI-Predictor have been developed to detect and grade DDIs. DDI-Predictor gives an estimate of the magnitude of an interaction based on the...
3.
Cuvelier E, Khazri H, Lecluse C, Hennart B, Amad A, Roche J, et al.
Pharmaceuticals (Basel)
. 2024 Jan;
17(1).
PMID: 38256855
To avoid the failures in therapy with psychotropic drugs, treatments can be personalized by applying the results of therapeutic drug monitoring and pharmacogenetic testing. The objective of the present single-center...
4.
Puszkiel A, You B, Payen L, Lopez J, Guitton J, Rousset P, et al.
Cancer Chemother Pharmacol
. 2023 Apr;
91(5):413-425.
PMID: 37010549
Purpose: The objective was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics and progression-free survival (PFS) based on data from EVESOR trial in patients...
5.
Varnier R, Puszkiel A, Tod M, Calattini S, Payen L, Lopez J, et al.
Cancer Chemother Pharmacol
. 2023 Feb;
91(5):361-373.
PMID: 36840749
Purpose: Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models. However, previous clinical studies were hampered by cumulative toxicities when both were given continuously. The...
6.
Tuloup V, Goutelle S, Tod M, Bourguignon L
Clin Pharmacokinet
. 2023 Jan;
62(2):307-319.
PMID: 36631686
Background And Objective: Chronic kidney disease (CKD) may alter drug renal elimination but is also known for interacting with hepatic metabolism via multiple uremic components. However, few global models, considering...
7.
Le Louedec F, Puisset F, Chatelut E, Tod M
Clin Pharmacokinet
. 2023 Jan;
62(1):55-66.
PMID: 36631685
Protein kinase inhibitors share pharmacokinetic (PK) pathways among themselves. They are all metabolized by several cytochromes P450 (CYP). For most of them, CYP3A4 is the predominant metabolic pathway. However, their...
8.
Joly F, Fabbro M, Berton D, Lequesne J, Anota A, Puszkiel A, et al.
Gynecol Oncol
. 2022 Jul;
166(3):389-396.
PMID: 35902297
Background: Anti-angiogenic rechallenge with bevacizumab plus chemotherapy is effective in recurrent ovarian cancer (rOC); however, data are limited on tyrosine kinase inhibitors after progression on maintenance bevacizumab. Methods: In the...
9.
Tod M, Rodier T, Auffret M
Drug Saf
. 2022 Jun;
45(7):755-764.
PMID: 35737292
Introduction: Iatrogeny due to drug-drug interactions is insufficiently documented, due to the high number of possible combinations. Objective: This study aimed to design a simple but general method to predict...
10.
You B, van Wagensveld L, Tod M, Sonke G, Horlings H, Kruitwagen R, et al.
Br J Cancer
. 2022 Apr;
127(1):79-83.
PMID: 35361918
Background: In ovarian carcinomas, the likelihood of disease cure following first-line medical-surgical treatment has been poorly addressed. The objective was to: (a) assess the likelihood of long-term disease-free (LDF) > ...